PubMedHealth treatment related to Pulmonary Hypertension: 63
Pulmonary hypertension (PH) has no cure. However, treatment may
help relieve symptoms and slow the progress of the disease.PH is treated with medicines, procedures, and other therapies.
Treatment will depend on what type of PH you have and its severity.
(For more information, go to "Types of Pulmonary
Hypertension.")
FDA approved drugs:
(show all 7)
# |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
1 |
|
Adcirca
18
|
TADALAFIL |
Eli Lilly |
May 2009 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II - III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). (1.1)
DrugBank Targets:
16
cGMP-specific 3',5'-cyclic phosphodiesterase|Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
Mechanism of Action:
18
Target: phosphodiesterase type 5 (PDE5)
Action: oral inhibitor
FDA: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. Studies in vitro have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in pulmonary vascular smooth muscle, visceral smooth muscle, corpus cavernosum, skeletal muscle, platelets, kidney, lung, cerebellum, and pancreas.In vitro studies have shown that the effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. These studies have shown that tadalafil is >10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes, which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle, and other organs. Tadalafil is >10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. Additionally, tadalafil is 700-fold more potent for PDE5 than for PDE6, which is found in the retina and is responsible for phototransduction. Tadalafil is >9,000-fold more potent for PDE5 than for PDE8, PDE9, and PDE10. Tadalafil is 14-fold more potent for PDE5 than for PDE11A1 and 40-fold more potent for PDE5 than for PDE11A4, two of the four known forms of PDE11. PDE11 is an enzyme found in human prostate, testes, skeletal muscle and in other tissues. In vitro, tadalafil inhibits human recombinant PDE11A1 and, to a lesser degree, PDE11A4 activities at concentrations within the therapeutic range. The physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.
|
2 |
|
Adempas
18
|
RIOCIGUAT |
Bayer Healthcare Pharmaceuticals |
October 2013 |
Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Indications and Usage:
18
Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)
DrugBank Targets:
-
Mechanism of Action:
18
Target: soluble guanylate cyclase (sGC)
Action: stimulator
FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.
|
3 |
|
Letairis
18
|
AMBRISENTAN |
Gilead |
June 2007 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): * To improve exercise ability and delay clinical worsening. * In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) (1).
DrugBank Targets:
16
Endothelin-1 receptor|Endothelin B receptor
Mechanism of Action:
18
Target: endothelin receptor
Action: type-A selective antagonist
FDA: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH. Ambrisentan is a high-affinity (Ki=0.011 nM) ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.
|
4 |
|
Opsumit
18
|
MACITENTAN |
Actelion Pharmaceuticals |
October 2013 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH (1.1).
DrugBank Targets:
16
Endothelin-1 receptor|Endothelin B receptor
Mechanism of Action:
18
Target: Endothelin Receptor
Action: antagonist
FDA: Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage. Macitentan is an endothelin receptor antagonist that prevents the binding of ET-1 to both ETA and ETB receptors. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is also pharmacologically active at the ET receptors and is estimated to be about 20% as potent as the parent drug in vitro.
|
5 |
|
Remodulin
18
|
TREPROSTINIL |
United Therapeutics |
May 2002 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
Remodulin is a prostacyclin vasodilator indicated for: * Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) * Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2)
DrugBank Targets:
16
Prostacyclin receptor|Peroxisome proliferator-activated receptor delta|P2Y purinoceptor 12
Mechanism of Action:
18
Target: pulmonary and systemic arterial vascular beds|platelet aggregation
Action: direct vasodilation|inhibition
FDA: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
|
6 |
|
Tracleer
18
|
BOSENTAN |
Actelion |
November 2001 |
Disease/s that Drug Treats:Pulmonary arterial hypertension
Indications and Usage:
18
Tracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) (1.1). Considerations for use: Consider whether benefits offset the risk of hepatotoxicity in WHO Class II patients. Early hepatotoxicity may preclude future use as disease progresses (1.1).
DrugBank Targets:
16
Endothelin B receptor|Endothelin-1 receptor
Mechanism of Action:
18
Target: endothelin receptor types ETA and ETB
Action: specific and competitive antagonist
FDA: Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. Bosentan has a slightly higher affinity for ETA receptors than for ETB receptors. The clinical impact of dual endothelin blockage is unknown. Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease.
|
7 |
|
Tyvaso
18
|
TREPROSTINIL |
United Therapeutics |
July 2009 |
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:
18
Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). (1)
DrugBank Targets:
16
Prostacyclin receptor|Peroxisome proliferator-activated receptor delta|P2Y purinoceptor 12
Mechanism of Action:
18
Target: -
Action: -
FDA: Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.
|
Drugs for Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 435)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bosentan |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
147536-97-8 |
104865
|
Synonyms:
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulphornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
bosentan
Bosentan
bosentán
Bosentan (INN)
Bosentan [USAN:INN:BAN]
bosentan anhydrous
Bosentan anhydrous
Bosentan hydrate
Bosentan monohydrate
bosentanum
Bosentanum
C27H29N5O6S
CHEBI:51450
|
CHEMBL957
CID104865
D07538
DB00559
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
PDSP1_001731
PDSP2_001714
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
P-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
P-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulphonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
|
|
2 |
|
Iloprost |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
78919-13-8 |
6443959
|
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
[3H]-Iloprost
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
CID9975807
|
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
Ilomedin
Ilomedine
Iloprost
ILOPROST
Iloprost (INN)
Iloprost [BAN:INN]
Iloprost-pe
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
|
|
3 |
|
Benzocaine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
94-09-7, 1994-09-7 |
2337
|
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl Aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
|
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-Aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-Aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
p-Ethoxycarboxylic Aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
4 |
|
tannic acid |
Approved |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
5 |
|
Spironolactone |
Approved |
Phase 4,Phase 2,Phase 1,Not Applicable |
|
52-01-7, 1952-01-7 |
5833
|
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone a
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alphapharm Brand of Spironolactone
Alpharma brand OF spironolactone
Alpharma Brand of Spironolactone
Alter brand OF spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Ashbourne Brand of Spironolactone
Azupharma brand OF spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
Betapharm brand OF spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel brand OF spironolactone
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
CT Arzneimittel brand OF spironolactone
ct-Arzneimittel Brand of Spironolactone
CT-Arzneimittel brand OF spironolactone
D00443
D013148
DB00421
Deverol
dexo Brand OF spironolactone
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona Alter
Espironolactona mundogen
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan brand OF spironolactone
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm brand OF spironolactone
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-spindler brand OF spironolactone
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura brand OF spironolactone
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
|
MLS002153245
MLS002207058
Mundogen brand OF spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
novo Spiroton
Novo Spiroton
Novopharm brand OF spironolactone
Novopharm Brand of Spironolactone
novo-Spiroton
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer brand OF spironolactone
Pfizer Brand of Spironolactone
Pharmafrid brand OF spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche brand OF spironolactone
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle brand OF spironolactone
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
spiro L.U.T.
Spiro L.U.T.
spiro von ct
spiro Von CT
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
spirono Isis
Spirono Isis
Spironocompren
spirono-Isis
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
Von CT, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Wörwag brand OF spironolactone
Xenalon
ZINC03861599
|
|
6 |
|
Iron |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
7439-89-6 |
23925
|
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
|
Fe-40
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
7 |
|
Tadalafil |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
171596-29-5 |
110635
|
Synonyms:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
351, IC
6-benzo[1,3]DIOXOL-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
Acdirca
Adcirca
ADCIRCA
C429886
CHEBI:41488
CHEMBL779
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
CID110635
CPD000466321
D02008
DB00820
FT-0080116
GF 196960
GF-196960
|
HMS2051N17
HSDB 7303
IC 351
Ic351
IC-351
ICOS 351
KS-1117
Lilly brand of tadalafil
LS-186558
LS-187015
LS-187770
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
|
|
8 |
|
Epoprostenol |
Approved |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
61849-14-7, 35121-78-9 |
5280427
5282411
|
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13e)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9alpha,11alpha,13e,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
Bio2_000216
Bio2_000696
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
|
CID6434194
CID6450541
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
epoprostenol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenol sodium
Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
KB-IV-24
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PGI(sub 2)
PGI2
PG-I2
PGX
prostacyclin
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
prostaglandin I2
Prostaglandin I2
Prostaglandin x
Prostaglandin X
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
|
|
9 |
|
Treprostinil |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
81846-19-7 |
54786
6918140
|
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
LRX 15
LS-177654
|
LS-187014
LS-187645
Orenitram
Remodulin
Remodulin (TN)
Trepostinil sodium
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil diolamine
Treprostinil sodium
treprostinilo
Treprostinilo
treprostinilum
Treprostinilum
U 62840
U-62,840
UNII-RUM6K67ESG
Uniprost
UT-15
Viveta
|
|
10 |
|
Warfarin |
Approved |
Phase 4,Phase 2 |
|
81-81-2 |
6691
54678486
|
Synonyms:
(-)-Warfarin
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine
(S)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
(S)-Warfarin
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
200 coumarin
200 Coumarin
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin
45706_FLUKA
45706_RIEDEL
4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin
4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine
4oh-Coumarin deriv.
5543-56-6
5543-57-7
81-81-2
A2250_FLUKA
A2250_SIGMA
AC-15978
AC1L1N37
AC1Q6AN3
aldo Brand OF warfarin sodium
Aldocumar
Antigen brand OF warfarin sodium
Apotex brand OF warfarin sodium
apo-Warfarin
AR-1E2310
Arab rat death
Arab Rat Death
Arab rat deth
Athrombin
Athrombine-K
Athrombin-K
Bailly brand OF warfarin sodium
Bio-0586
Boots brand OF warfarin sodium
BRD-A24514565-001-02-2
BRD-A24514565-236-01-6
Bristol-myers squibb brand OF warfarin sodium
BRN 1293536
Brumolin
BSPBio_002026
C01541
C19H16O4
Caswell No. 903
CBDivE_002127
CBDivE_013236
CBKinase1_000192
CBKinase1_012592
CHEBI:10033
CHEMBL1464
Choice
Choice (TN)
CID6691
Compound 42
Co-Rax
CO-Rax
Coumadin
Coumadin Tabs
Coumadine
Coumafen
Coumafene
Coumafene [French]
Coumaphen
Coumaphene
Coumarins
Coumefene
Cov-R-tox
Cov-R-Tox
D08682
DB00682
D-Con
D-CON
delta-CON
Dethmor
Dethnel
Dicusat e
Dicusat E
DivK1c_000444
DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
Eastern states duocide
EINECS 201-377-6
EINECS 226-907-3
EPA Pesticide Chemical Code 086002
Estedi brand OF warfarin sodium
fasco Fascrat powder
Fasco fascrat powder
Frass-ratron
Frass-Ratron
Genpharm brand OF warfarin sodium
Gen-warfarin
Goldshield brand OF warfarin sodium
HMS1921K07
HMS2092C20
HMS501G06
HSDB 1786
I14-0958
IDI1_000444
Jantoven
KBio1_000444
KBio2_000674
KBio2_003242
KBio2_005810
KBio3_001526
KBioGR_000901
KBioSS_000674
Killgerm sewarin P
Kumader
Kumadu
Kumatox
Kypfarin
Latka 42
Latka 42 [Czech]
Liqua-tox
LS-55083
Maag rattentod cum
Maag Rattentod Cum
Marevan
Mar-frin
|
Mar-Frin
Martin's mar-frin
Martin'S mar-frin
Maveran
MLS001304042
MolPort-001-787-822
Mouse pak
NCGC00094810-01
NCGC00094810-02
NCGC00159398-03
NCGC00178855-01
nchembio.307-comp19
NINDS_000444
NSC 59813
NSC59813
Panwarfin
Place-pax
Place-Pax
Potassium, warfarin
Prothromadin
PS104_SUPELCO
rac-Warfarin
Rat & mice bait
Rat and mice bait
Rat-alpha-way
Rat-a-way
Rat-beta-gon
Rat-b-gon
Rat-B-gon
Rat-gard
Rat-Gard
Rat-kill
Rat-Kill
Rat-mix
Rat-Mix
Rat-o-cide #2
Rat-O-cide #2
Rat-O-cide no. 2
Rat-ola
Rat-Ola
Ratorex
Ratox
Ratoxin
Ratron
Ratron g
Ratron G
Rats-no-more
Rats-NO-more
Ratten-koederrohr
Ratten-Koederrohr
Rattenstreupulver neu schacht
Rattenstreupulver Neu Schacht
Rattenstreupulver new schacht
Rattentraenke
Rat-trol
Rat-Trol
Rattunal
RAX
RCR Grey squirrel killer concentrate
RCRA waste no. P001
Rcra waste number P001
Rodafarin
Rodafarin c
Rodafarin C
ro-Deth
Ro-Deth
Rodex
Rodex blox
Rosex
Rough & ready mouse mix
Rough and ready mouse mix
Sakarat
Sewarin
SMP1_000316
SMR000718754
Sodium, warfarin
Sofarin
Solfarin
Sorexa plus
Sorexa Plus
SPBio_000870
Spectrum_000194
SPECTRUM1500613
Spectrum2_000935
Spectrum3_000583
Spectrum4_000381
Spectrum5_001751
Spray-trol brand roden-trol
STK364490
Tedicumar
Temus W
Tintorane
Tox-hid
Tox-Hid
Twin light rat away
UNII-5Q7ZVV76EI
Vampirinip II
Vampirinip iii
Vampirinip III
W.A.R.F. 42
Waran
Warf 10
Warf 42
WARF compound 42
Warfant
Warfarat
warfarin
Warfarin (and salts of)
Warfarin (INN)
Warfarin [BSI:ISO]
Warfarin [INN:BAN]
Warfarin plus
Warfarin Plus
Warfarin plus [discontinued]
Warfarin potassium
Warfarin Q
Warfarin sodium
Warfarin titrated to an INR of 2.5-3.0
Warfarin(R)
Warfarina
Warfarina [INN-Spanish]
Warfarine
Warfarine [INN-French]
Warfarine [ISO-French]
Warfarinum
Warfarinum [INN-Latin]
Warficide
Warfilone
WLN: T66 BOVJ DYR&1V1 EQ
Zoocoumarin
Zoocoumarin [Netherlands and USSR]
Zoocoumarin [Russian]
|
|
11 |
|
Heparin |
Approved, Investigational |
Phase 4,Phase 3 |
|
9005-49-6 |
772
46507594
|
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
heparina
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
12 |
|
Nitric Oxide |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
10102-43-9 |
145068
|
Synonyms:
(.)NO
(no)(.)
(NO)(.)
[no]
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
monoxido De nitrogeno
Monoxido de nitrogeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
nitric oxide
|
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
no(.)
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
óxido de nitrógeno(2)
oxido de nitrogeno(II)
oxido De nitrogeno(II)
Oxido de nitrogeno(ii)
oxido nitrico
oxido Nitrico
Oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(ii)-oxid
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
13 |
|
Ambrisentan |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
177036-94-1 |
6918493
|
Synonyms:
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid
177036-94-1
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid
2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
AC1L53VT
Ambrisentan
Ambrisentan [INN]
Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe
BSF 208075
BSF208075
BSF-208075
C467894
CHEBI:205299
CHEMBL302753
|
CID197712
Gilead brand of ambrisentan
I06-2077
Letairis
LS-186563
LS-187364
LU 208075
LU208075
LU-208075
MLS001195278
MolPort-002-945-567
NCGC00160662-01
SMR000502713
ST51051295
STK097095
UNII-HW6NV07QEC
|
|
14 |
|
Macitentan |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
441798-33-0 |
|
Synonyms:
|
15 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4,Phase 1,Not Applicable |
|
137-58-6 |
3676
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
|
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
16 |
|
Ranolazine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
142387-99-3, 95635-55-5 |
56959
|
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
Dihydrochloride, ranolazine
HCL, Ranolazine
HMS1922F16
HMS2090L09
HMS2093D21
Hydrochloride, ranolazine
I01-2008
I06-0160
KEG-1295
Latixa
Lopac0_001062
LS-187267
MLS002154149
MolPort-003-666-653
|
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
ranolazine
RANOLAZINE
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine Dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
|
|
17 |
|
Dalteparin |
Approved |
Phase 4,Phase 3 |
|
9005-49-6 |
|
Synonyms:
|
18 |
|
Isoflurane |
Approved, Vet_approved |
Phase 4 |
|
26675-46-7 |
3763
|
Synonyms:
1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
1-chloro-2,2,2-Trifluoroethyl difluoromethyl ether
1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether
26675-46-7
2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
AC-154802
AC1L1GNN
Aerrane
AErrane (Veterinary)
BRN 1852087
C07518
CCRIS 3043
CHEBI:6015
CHEMBL1256
CID3763
Compound 469
D00545
D007530
DB00753
EINECS 247-897-7
Ethane
Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl
|
Forane
Forane (TN)
Forene
I14-1303
IsoFlo
isoflurane
Isoflurane
Isoflurane (JP15/USP/INN)
Isoflurane [Anaesthetics, volatile]
Isoflurane [Usan:Ban:Inn:Jan]
Isoflurane [USAN:BAN:INN:JAN]
Isoflurane [USAN:INN:BAN:JAN]
Isoflurano
Isoflurano [INN-Spanish]
Isofluranum
Isofluranum [INN-Latin]
Jsp005223
LS-7462
MolPort-000-153-606
NCGC00181037-01
R-E 235dal
ST51041445
UNII-CYS9AKD70P
|
|
19 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943
|
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
20 |
|
Clevidipine |
Approved, Investigational |
Phase 4 |
|
167221-71-8 |
|
Synonyms:
|
21 |
|
Zinc |
Approved, Investigational |
Phase 4,Not Applicable |
|
7440-66-6 |
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
22 |
|
Magnesium oxide |
Approved |
Phase 4 |
|
1309-48-4 |
14792
|
Synonyms:
|
23 |
|
Silver sulfadiazine |
Approved, Vet_approved |
Phase 4 |
|
22199-08-2 |
441244
|
Synonyms:
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
22199-08-2
481181_ALDRICH
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Abbott Brand of Silver Sulfadiazine
AC-19319
AC1L1KQS
AC1L9ATF
AC1L9Q6O
AC1NUR63
AC1O8LAG
AC-3535
AKOS005111099
AKOS005111434
Aldo Brand of Silver Sulfadiazine
ARONIS23842
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex
Brandiazin
C10H9N4O2S.Ag
CHEBI:9142
CHEMBL1200766
CID11947738
CID31011
CID441244
CID452254
CID5459124
D00433
D012837
DB05245
Dermazin
Dermazine
EINECS 244-834-5
Flamazine
Flammazine
Geben
I06-0145
I06-145
LS-147839
Major Brand of Silver Sulfadiazine
medphano Brand of Silver Sulfadiazine
MLS000069662
MolPort-003-934-423
MolPort-003-986-619
MolPort-006-395-987
Monarch Brand of Silver Sulfadiazine
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NSC 625324
NSC625324
|
Par Brand 1 of Silver Sulfadiazine
Par Brand 2 of Silver Sulfadiazine
Par Brand 3 of Silver Sulfadiazine
Pharmascience Brand of Silver Sulfadiazine
Rhone Poulenc Rorer Brand of Silver Sulfadiazine
Rhone-Poulenc Rorer Brand of Silver Sulfadiazine
S0595
Sherwood Brand of Silver Sulfadiazine
Sicazine
Silbertone
Sildaflo
Silvadene
Silvadene (TN)
Silvederma
silver
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
silver sulfadiazinate
Silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine
Silver Sulfafdiazine
Silver sulphadiazine
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
Silver(I) sulfadiazine
Smith & Nephew Brand of Silver Sulfadiazine
SMR000059233
Solvay Brand of Silver Sulfadiazine
SSD
SSD (1% Silver Sulfadiazine Cream USP)
SSD AF
STL069502
Sulfadiazin silber
Sulfadiazin, silbersalz
Sulfadiazine silver
SULFADIAZINE SILVER
Sulfadiazine silver (JP15)
Sulfadiazine silver salt
Sulfadiazine silverSilvadene
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, Silver [USAN]
Sulfafdiazine, Silver
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt
Sulfargen
Thermazene
TL8001845
UNII-W46JY43EJR
Zenith Brand of Silver Sulfadiazine
|
|
24 |
|
Acetazolamide |
Approved, Vet_approved |
Phase 4,Phase 2,Phase 3 |
|
59-66-5 |
1986
|
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2-acetylamino-1,3,4-Thiadiazole-5-sulphonamide
2h4n
3czv
4-Diamox
5661-25-6
59-66-5
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
5-acetamido-1,3,4-THIADIAZOLE-2-sulfonamide
5-acetamido-1,3,4-THIADIAZOLE-2-sulphonamide
5-acetylamino-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulphonamide
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
acetazolamide
Acétazolamide
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide [INN:BAN:JAN]
Acetazolamide apotex brand
Acetazolamide Apotex Brand
Acetazolamide chiesi brand
Acetazolamide Chiesi Brand
Acetazolamide dioptic brand
Acetazolamide Dioptic Brand
Acetazolamide grin brand
Acetazolamide Grin Brand
Acetazolamide icn brand
Acetazolamide ICN Brand
Acetazolamide jumer brand
Acetazolamide Jumer Brand
Acetazolamide llorens brand
Acetazolamide Llorens Brand
Acetazolamide medphano brand
Acetazolamide Medphano Brand
Acetazolamide novopharm brand
Acetazolamide Novopharm Brand
Acetazolamide orion brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide sodium, (sterile)
Acetazolamide Sodium, (Sterile)
Acetazolamide wassermann brand
Acetazolamide Wassermann Brand
Acetazolamide, monosodium salt
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
AI3-52458
Ak zol
Ak Zol
AKOS000715163
Ak-zol
AkZol
Ak-Zol
apo Acetazolamide
Apo Acetazolamide
apo-Acetazolamide
ApoAcetazolamide
Apo-Acetazolamide
Apotex brand OF acetazolamide
Apotex Brand of Acetazolamide
Atenezol
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
Carbonic anhydrase inhibitor 6063
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
Chiesi brand OF acetazolamide
Chiesi Brand of Acetazolamide
Ciba vision brand OF acetazolamide
Ciba Vision Brand of Acetazolamide
CID1986
Cidamex
CPD000058394
CPD0-1626
Cyanamid brand OF acetazolamide preparation
D000086
D00218
Dazamide
DB00819
Defiltran
Défiltran
Dehydratin
Diacarb
Diakarb
Diamox
Diamox (TN)
|
Diamox Sequels
Didoc
Diluran
Dioptic brand OF acetazolamide
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-holzinger
Diureticum-Holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
Edemox
EINECS 200-440-5
EU-0100039
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin brand OF acetazolamide
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma zolamide
Huma Zolamide
Huma-zolamide
HumaZolamide
Huma-Zolamide
I09-0425
ICN brand OF acetazolamide
ICN Brand of Acetazolamide
IDI1_000017
Jumer brand OF acetazolamide
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
Lederle brand OF acetazolamide preparation
Llorens brand OF acetazolamide
Llorens Brand of Acetazolamide
Lopac0_000039
Lopac-A-6011
LS-10227
medphano Brand OF acetazolamide
Medphano Brand of Acetazolamide
MLS000028435
MLS001148438
MolPort-001-783-578
Monosodium salt acetazolamide
Monosodium Salt Acetazolamide
N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
N-[5-(Aminosulphonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulphonyl)-1,3,5-thiadiazol-2-yl]acetamide
Natrionex
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
Nephramid
Nephramide
NINDS_000017
Novopharm brand OF acetazolamide
Novopharm Brand of Acetazolamide
NSC 145177
NSC145177
Orion brand OF acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick_4
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
SAM002554883
SBB056640
Sk-Acetazolamide
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
Spectrum_000018
SPECTRUM1500102
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Storz brand OF acetazolamide preparation
Storz Brand of Acetazolamide Preparation
Storzolamide
Théraplix brand OF acetazolamide preparation
UNII-O3FX965V0I
Vetamox
Wassermann brand OF acetazolamide
Wassermann Brand of Acetazolamide
Whelehan brand OF acetazolamide preparation
WLN: T5NN DSJ CSZW EMV1
Wyeth brand OF acetazolamide preparation
Wyeth Brand of Acetazolamide Preparation
|
|
25 |
|
Poractant alfa |
Approved |
Phase 4,Phase 3 |
|
129069-19-8 |
|
26 |
|
Selexipag |
Approved |
Phase 4,Phase 3,Phase 2 |
|
475086-01-2 |
|
27 |
|
Ibuprofen |
Approved |
Phase 4,Phase 3,Not Applicable |
|
15687-27-1 |
3672
|
Synonyms:
(+-)-2-(P-Isobutylphenyl)propionate
(+-)-2-(P-Isobutylphenyl)propionic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetate
(+-)-a-Methyl-4-(2-methylpropyl)benzeneacetic acid
(+-)-Ibuprofen
(+-)-P-Isobutylhydratropate
(+-)-P-Isobutylhydratropic acid
(+-)-α-methyl-4-(2-methylpropyl)benzeneacetate
(+-)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
(±)-2-(p-isobutylphenyl)propionic acid
(±)-ibuprofen
(±)-p-isobutylhydratropic acid
(±)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
(4-Isobutylphenyl)-alpha-methylacetate
(4-Isobutylphenyl)-alpha-methylacetic acid
(4-Isobutylphenyl)-a-methylacetate
(4-Isobutylphenyl)-a-methylacetic acid
(4-Isobutylphenyl)-α-methylacetate
(4-isobutylphenyl)-α-methylacetic acid
(4-Isobutylphenyl)-α-methylacetic acid
(RS)-ibuprofen
(RS)-Ibuprofen
139466-08-3
15687-27-1
2-(4-Isobutylphenyl)propanoate
2-(4-isobutylphenyl)propanoic acid
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropate
4-isobutylhydratropic acid
4-Isobutylhydratropic acid
58560-75-1
a-(4-Isobutylphenyl)propionate
a-(4-Isobutylphenyl)propionic acid
a-(P-Isobutylphenyl)propionate
a-(P-Isobutylphenyl)propionic acid
AC-11312
AC1L1GGE
AC1Q1P84
AC1Q1P85
ACHES-N-PAIN
Act-3
Actiprofen
Adex 200
Adran
Advil
Advil (TN)
Advil Liqui-Gels
Ak+C2278tren
Alaxan
Algofen
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(P-Isobutylphenyl)propionate
alpha-(P-Isobutylphenyl)propionic acid
alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
alpha-P-Isobutylphenylpropionate
alpha-P-Isobutylphenylpropionic acid
Aluminum salt ibuprofen
Amelior
Amersol
Am-Fam 400
Amibufen
Anafen
Anco
Andran
Anflagen
Antagil
Antalfene
Antarene
Antiflam
Apo-Ibuprofen
Apsifen
Apsifen-F
ARONIS23835
Artofen
Artril
Artril 300
Balkaprofen
BB_SC-1358
Betaprofen
BIDD:GT0050
Bloom
Bluton
BRN 2049713
Brofen
Brufanic
Brufen
Brufen 400
Bruflam
Brufort
Buburone
Bufeno
Bufigen
Bukrefen
Bupron
Buracaps
Burana
Butylenin
C01588
C13H18O2
Calcium salt ibuprofen
Cap-Profen
Carol
CCRIS 3223
Cesra
CHEBI:5855
CHEMBL521
Children's Advil
Children's Elixsure
Children's Ibuprofen
Children's Motrin
CID3672
Citalgan
Cobo
Codral
Combiflam
CPD000058184
Cunil
D00126
D007052
Daiprophen
Dalsy
Dansida
DB01050
Deep Relief
Dentigoa
Dibufen
Dignoflex
Dolgin
Dolgirid
Dolgit
Dolibu
Dolmaral
DOLO PUREN
Dolocyl
dolo-Dolgit
Dolo-Dolgit
Dolofen
Dolofen-F
Dolofin
Dolofort
Dologel
Dolomax
Doloren
Dolormin
Doltibil
Dolven
Donjust B
Dorival
Drin
Duafen
Duobrus
Dura-Ibu
Duralbuprofen
Dysdolen
Easifon
Ebufac
Emflam
Emflam-200
Emodin
Epobron
Eputex
Ergix
Esprenit
EU-0100691
Exneural
Faspic
Femadon
Femafen
Femapirin
Femidol
Fenbid
Fenbid Spansule
Fendol
Fenspan
Fibraflex
Gelufene
Gofen
Grefen
Gynofug
Haltran
HMS1920F15
HMS2089P05
HMS2091N03
HMS502M09
HSDB 3099
I 4883
I.V. solution, ibuprofen
I01-7039
I0415
I4883_SIGMA
I7905_SIAL
IB-100
Ibol
Ibren
Ibu
Ibu-attritin
Ibu-Attritin
Ibubest
Ibubeta
Ibucasen
Ibudol
Ibudolor
Ibufen
Ibuflamar
|
Ibufug
Ibugel
Ibugen
Ibugesic
Ibuhexal
Ibulagic
Ibular
Ibulav
Ibuleve
Ibulgan
Ibumed
Ibumerck
Ibumetin
Ibupirac
Ibuprin
Ibuprocin
ibuprofen
Ibuprofen i.v. solution
Ibuprofen zinc
Ibuprofen, (+-)-isomer
Ibuprofen, (R)-isomer
Ibuprofen, (S)-isomer
Ibuprofen, aluminum salt
Ibuprofen, calcium salt
Ibuprofen, copper (2+) salt
Ibuprofen, magnesium salt
Ibuprofen, potassium salt
Ibuprofen, sodium salt
Ibuprofen, zinc salt
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprofen-zinc
Ibuprohm
Ibuprophen
Ibusal
Ibu-slo
Ibu-Slo
Ibu-slow
Ibu-Tab
Ibu-Tab 200
Ibutid
IDI1_000887
Ifen
Inabrin
Inflam
Inoven
IP 82
IP82
IP-82
Ipren
Irfen
Isodol
Jenaprofen
Junifen
Junior Strength Advil
Junior Strength Ibuprofen
Junior Strength Motrin
KBio1_000887
KBio2_001329
KBio2_003897
KBio2_006465
KBio3_001390
Kesan
Kratalgin
Lamidon
Lebrufen
Librofem
Lidifen
Liptan
Lopane
LS-7454
Magnesium salt ibuprofen
Malafene
Manypren
Medipren
Melfen
Mensoton
Midol
Midol 200
MLS000069733
MLS001146965
Moment
Motrin
Motrin (TN)
Motrin IB
Mynosedin
Nagifen-D
Napacetin
Narfen
NCI60_002065
Neobrufen
Neo-Helvagit
Neo-Mindol
NeoProfen
Nerofen
NINDS_000887
Noalgil
Nobafon
Nobfelon
Nobfen
Nobgen
Noritis
Norton
Novadol
Novogent
Novogent N
Novoprofen
Novo-Profen
NSC 256857
NSC256857
Nuprilan
Nuprin
Nurofen
Optifen
Opturem
Oralfene
Ostarin
Ostofen
Ozonol
Paduden
Panafen
Pantrop
Para-Isobutylhydratropic Acid
Paxofen
Pediaprofen
PediaProfen
Pedia-Profen
Pediatric Advil
Perofen
P-Isobutyl-2-phenylpropionate
P-Isobutyl-2-phenylpropionic acid
P-Isobutylhydratropate
P-Isobutylhydratropic acid
P-Isobutylhydratropic Acid
Potassium salt ibuprofen
Proartinal
Profen
Proflex
Provon
Quadrax
R.D. 13621
Rafen
Ranofen
RD 13621
Rebugen
Relcofen
Rhinadvil
Rofen
Roidenin
Rufen
Rufin
Rupan
Sadefen
Salivia
Salprofen
Salt ibuprofen, magnesium
Salt ibuprofen, sodium
Salt ibuprofen, zinc
SAM002264619
Seclodin
Sednafen
Seklodin
Seskafen
Siyafen
SMR000058184
Sodium salt ibuprofen
Solpaflex
Solufen
SPBio_000178
Stelar
STK177358
Sugafen
Suprafen
Suspren
Syntofene
Tabalon
Tabalon 400
Tab-Profen
Tatanal
Tempil
TL8001184
Tofen
Togal N
Tonal
Trauma dolgit gel
Trauma-dolgit gel
TraumaDolgit gel
Trendar
U 18573
U-18,573
U-18573
UCB 79171
Unipron
Upfen
Uprofen
Urem
VUFB 9649
Zafen
Zinc salt ibuprofen
Zofen
α-(4-isobutylphenyl)propionate
α-(4-isobutylphenyl)propionic acid
α-(P-isobutylphenyl)propionate
α-(p-isobutylphenyl)propionic acid
α-(P-isobutylphenyl)propionic acid
|
|
28 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206
|
Synonyms:
1,1,1,3,3,3-hexafluoro-2-(Fluoromethoxy)propane
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
Bax 3084
BRN 2041023
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
fluoromethyl hexafluoroisopropyl ether
Fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
|
LS-67851
MolPort-001-775-746
MR_6S4
MR6S4
NCGC00167421-01
PC4681
Sevofluran
sevoflurane
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
Ultane
Ultane (TN)
UNII-38LVP0K73A
ZINC01530810
|
|
29 |
|
Nebivolol |
Approved, Investigational |
Phase 4 |
|
99200-09-6, 152520-56-4, 118457-14-0 |
71301
|
Synonyms:
1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
104365-59-5
118457-14-0
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
99200-09-6
a,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
AC-1611
AC1L2FX8
AC1Q4OMF
alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,Alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol)
Bystolic
C22H25F2NO4
CHEMBL434394
CID71301
D05127
DB04861
Hydrochloride, nebivolol
I06-0378
L001284
|
Lobivon
LS-178404
MolPort-003-849-343
Narbivolol
Nebicard-5
Nebilet
Nebilong
Nebipill
Nebivolol
Nebivolol (USAN/INN)
Nebivolol [USAN:INN:BAN]
Nebivolol hydrochloride
Nebivololum
nebivololum [latin]
Nebivololum [Latin]
Nodon
Nubeta
PDSP1_000244
PDSP2_000243
PI-21858
R 67555
R65,824
R-67555
Silostar
UNII-030Y90569U
α,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
|
|
30 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474
|
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(±)-bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
15233-43-9
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
2180-92-9
38396-39-3
AB00053674
Abbott brand OF bupivacaine hydrochloride
AC1L1DRE
AC1Q5LX4
AC-2096
AH 250
AKOS001637202
Anekain
Anhydrous, bupivacaine
AR-1A0242
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bio-0886
Bloqueina
BPBio1_000298
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bucaine
Bucaine (TN)
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
bupivacaine
Bupivacaine (INN)
Bupivacaine [INN:BAN]
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine HCL KIT
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacaine Monohydrochloride, Monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
C07529
C18H28N2O
Carbonate, bupivacaine
Carbostesin
cBupivacaine
CBupivacaine
CHEBI:3215
CHEMBL1098
|
CID2474
D07552
DB00297
DepoBupivacaine
DivK1c_000758
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
Dolanaest
DUR-843
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
Hydrochloride, bupivacaine
IDI1_000758
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MLS001361336
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Pisa brand OF bupivacaine hydrochloride
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SMR000058218
SPBio_001558
SPBio_002489
Spectrum_001524
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
|
|
31 |
|
Morphine |
Approved, Investigational |
Phase 4,Phase 2 |
|
57-27-2 |
5288826
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
32 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
77-92-9 |
311
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
33 |
|
Serine |
Approved, Nutraceutical |
Phase 4,Phase 1 |
|
56-45-1 |
5951
|
Synonyms:
(-)-Serine
(2S)-2-amino-3-Hydroxypropanoate
(2S)-2-amino-3-Hydroxypropanoic acid
(S)-(-)-Serine
(S)-2-amino-3-Hydroxypropanoate
(S)-2-amino-3-Hydroxy-propanoate
(S)-2-amino-3-Hydroxypropanoic acid
(S)-2-amino-3-Hydroxy-propanoic acid
(S)-2-Amino-3-hydroxypropanoic acid
(S)-a-amino-b-Hydroxypropionate
(S)-a-amino-b-Hydroxypropionic acid
(S)-alpha-amino-beta-Hydroxypropionate
(S)-alpha-amino-beta-Hydroxypropionic acid
(S)-b-amino-3-Hydroxypropionate
(S)-b-amino-3-Hydroxypropionic acid
(S)-beta-amino-3-Hydroxypropionate
(S)-beta-amino-3-Hydroxypropionic acid
(S)-Serine
(S)-α-amino-β-hydroxypropionate
(S)-α-amino-β-hydroxypropionic acid
2-amino-3-Hydroxypropanoate
2-amino-3-Hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
L Serine
L-(-)-Serine
L-2-amino-3-Hydroxypropionate
L-2-amino-3-Hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
β-hydroxyalanine
β-hydroxy-L-alanine
|
|
34 |
|
Tezosentan |
Investigational |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
180384-57-0 |
|
35 |
|
Beraprost |
Investigational |
Phase 4,Phase 3,Phase 2 |
|
88430-50-6 |
|
36 |
|
Lactitol |
Investigational |
Phase 4 |
|
585-86-4 |
3871
|
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
lactitol
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
37 |
|
Vasodilator Agents |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
38 |
|
Sildenafil Citrate |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
171599-83-0 |
|
39 |
|
Endothelin Receptor Antagonists |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
40 |
|
Citrate |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
41 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
42 |
|
Antihypertensive Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
43 |
|
Phosphodiesterase Inhibitors |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
44 |
|
Platelet Aggregation Inhibitors |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
45 |
|
Diuretics, Potassium Sparing |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
46 |
|
diuretics |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
47 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
48 |
|
Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
49 |
|
Mineralocorticoids |
|
Phase 4,Phase 2,Phase 1,Not Applicable |
|
|
|
50 |
|
Hormones |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1155)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia |
Unknown status |
NCT01449253
|
Phase 4 |
Sildenafil;Bosentan |
2 |
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) |
Unknown status |
NCT01116063
|
Phase 4 |
Inhaled iloprost |
3 |
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study |
Unknown status |
NCT00637065
|
Phase 4 |
Bosentan;Placebo |
4 |
Riociguat for Sarcoidosis Associated Pulmonary Hypertension |
Unknown status |
NCT02625558
|
Phase 4 |
Riociguat;Placebo |
5 |
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. |
Unknown status |
NCT02963597
|
Phase 4 |
|
6 |
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension |
Unknown status |
NCT01468571
|
Phase 4 |
Spironolactone;Placebo |
7 |
Iron Deficiency In Pulmonary Hypertension |
Unknown status |
NCT01288651
|
Phase 4 |
Ferricarboxymaltose |
8 |
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost |
Unknown status |
NCT01649739
|
Phase 4 |
Levitra |
9 |
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. |
Unknown status |
NCT00705588
|
Phase 4 |
Tadalafil;Vardenafil |
10 |
Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism |
Unknown status |
NCT02029456
|
Phase 4 |
25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours |
11 |
Hemodynamic Response After Six Months of Sildenafil |
Unknown status |
NCT00483626
|
Phase 4 |
oral sildenafil |
12 |
Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure |
Unknown status |
NCT00793338
|
Phase 4 |
Sildenafil |
13 |
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain |
Unknown status |
NCT01615627
|
Phase 4 |
HypotonicTreprostinil Solution;Eutonic Treprostinil Solution |
14 |
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy |
Unknown status |
NCT02979561
|
Phase 4 |
Dabigatran Etexilate;Warfarin |
15 |
Targeting the Right Ventricle in Pulmonary Hypertension |
Completed |
NCT01839110
|
Phase 4 |
Ranolazine;Placebo |
16 |
PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension |
Completed |
NCT02378649
|
Phase 4 |
Sildenafil;Placebo |
17 |
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction |
Completed |
NCT02133352
|
Phase 4 |
Ranolazine |
18 |
VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension |
Completed |
NCT01889966
|
Phase 4 |
Sildenafil |
19 |
Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension |
Completed |
NCT01055405
|
Phase 4 |
Sildenafil |
20 |
Natrecor for Pulmonary Hypertension in Lung Transplants |
Completed |
NCT00205426
|
Phase 4 |
Natrecor |
21 |
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan |
Completed |
NCT01051960
|
Phase 4 |
Ambrisentan |
22 |
Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns |
Completed |
NCT01757782
|
Phase 4 |
Oral Sildenafil;Placebo (distilled water) |
23 |
Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease |
Completed |
NCT00862043
|
Phase 4 |
Sildenafil Citrate;Placebo |
24 |
Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism |
Completed |
NCT02132689
|
Phase 4 |
Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy) |
25 |
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension |
Completed |
NCT01330108
|
Phase 4 |
ambrisentan |
26 |
Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD) |
Completed |
NCT00491803
|
Phase 4 |
Sildenafil;Sildenafil |
27 |
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension |
Completed |
NCT00403650
|
Phase 4 |
Iloprost |
28 |
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) |
Completed |
NCT02191137
|
Phase 4 |
Riociguat (Adempas, BAY63-2521) |
29 |
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension |
Completed |
NCT00004754
|
Phase 4 |
epoprostenol |
30 |
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children |
Completed |
NCT03431649
|
Phase 4 |
Beraprost Sodium;Sildenafil Citrate |
31 |
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH. |
Completed |
NCT01800292
|
Phase 4 |
sildenafil |
32 |
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement |
Completed |
NCT01717209
|
Phase 4 |
Nitric Oxide;Prostacyclin |
33 |
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin |
Completed |
NCT00373360
|
Phase 4 |
treprostinil sodium |
34 |
Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance |
Completed |
NCT01212523
|
Phase 4 |
propofol and isoflurane |
35 |
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). |
Completed |
NCT00878878
|
Phase 4 |
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension);Dextrose |
36 |
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00058929
|
Phase 4 |
treprostinil sodium |
37 |
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude |
Completed |
NCT02024386
|
Phase 4 |
Riociguat |
38 |
BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00367770
|
Phase 4 |
Tracleer® |
39 |
Effects of Viagra on Heart Function in Patients With Heart Failure |
Completed |
NCT00781508
|
Phase 4 |
sildenafil |
40 |
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed |
Completed |
NCT01121458
|
Phase 4 |
Clevidipine |
41 |
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication |
Completed |
NCT01268553
|
Phase 4 |
Treprostinil |
42 |
Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis |
Completed |
NCT01060020
|
Phase 4 |
Sildenafil |
43 |
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) |
Completed |
NCT02847260
|
Phase 4 |
Remodulin |
44 |
Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men. |
Completed |
NCT02595684
|
Phase 4 |
Tadalafil;Placebo |
45 |
Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients |
Completed |
NCT01996124
|
Phase 4 |
Indacaterol Fumarate;Placebo |
46 |
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT00303459
|
Phase 4 |
bosentan;placebo |
47 |
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects |
Completed |
NCT00741819
|
Phase 4 |
Inhaled treprostinil |
48 |
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) |
Completed |
NCT00617305
|
Phase 4 |
Ambrisentan;Placebo;Sildenafil;Tadalafil |
49 |
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis |
Completed |
NCT01042158
|
Phase 4 |
tadalafil and ambrisentan upfront combination therapy |
50 |
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension |
Completed |
NCT00323297
|
Phase 4 |
Bosentan;Bosentan;Sildenafil Citrate |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Pulmonary Hypertension:
Embryonic/Adult Cultured Cells Related to Pulmonary Hypertension:
|